Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25625286 | 0.87 | POLB (0.42) | KCNA5POLBMEN1KMT2ATACR3 | |
| SCHEMBL24036731 | 0.85 | WDR5 (0.50) | MEN1KMT2ATACR3ALDH1A1WDR5 | |
| SCHEMBL24036950 | 0.85 | TACR3 (0.39) | KCNA5POLBMEN1KMT2ATACR3 | |
| SCHEMBL24036947 | 0.82 | L3MBTL1 (0.40) | KCNA5MEN1KMT2ATACR3MAPT | |
| SCHEMBL25754069 | 0.82 | POLB (0.39) | KCNA5POLBMEN1KMT2ATACR3 | |
| SCHEMBL24036757 | 0.82 | POLB (0.39) | KCNA5POLBMEN1KMT2ATACR3 | |
| SCHEMBL25625540 | 0.81 | PNMT (0.46) | POLBMEN1KMT2AHTTNPSR1 | |
| SCHEMBL24036756 | 0.81 | POLB (0.38) | KCNA5POLBMEN1KMT2AHSD17B10 | |
| SCHEMBL24036726 | 0.81 | ROCK2 (0.39) | POLBKMT2ATACR3WDR5 | |
| SCHEMBL7358671 | 0.81 | ALDH1A1 (0.48) | MEN1KMT2ACYP26A1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2021230325-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | 宇部興産株式会社 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | KCNA5 1043/4885POLB 860/4885MEN1 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.